Thomas Cahill is Director at Prime Medicine, Inc. (PRME). They have made 1 open-market trade across 1 company since 2022, most recently 2022-10-24.
CIK 0001922939
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $6.8M since 2022, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| PRME | 4,905,679 | $17.0M |
Shares reported on the most recent Form 4, priced at the 2022-10-26 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PRME | BUY | 2022-10-24 | 2022-10-26 | $17.00 | $6.8M | +10.3% | +25.9% | +2.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.